Information Provided By:
Fly News Breaks for September 13, 2018
INCY, CNCE
Sep 13, 2018 | 08:42 EDT
As previously reported, Janney Montgomery Scott initiated Concert Pharmaceuticals (CNCE) with a Neutral rating, with analyst Esther Hong setting a $17 fair value estimate on the shares. She believes AVP-786, which is in Phase 3 in Alzheimer's agitation, has blockbuster potential and she is positive on its lead program, CTP-543 for the treatment of Alopecia Areata. However, Hong remains on the sidelines pending the final decision on CTP-543's patent after Incyte filed an Inter Partes Review petition, noting that the PTAB granted a rehearing request, which it rarely does. She sees the IPR ruling as difficult to predict at this stage.
News For CNCE;INCY From the Last 2 Days
There are no results for your query CNCE;INCY